Parkin WT
is prevented when co-transfected with members of the DNAJA subfamily (*=p<0.05; **=p<0.01; ***=p<0.001; n>3 independent samples, mean ± SEM). DNAJA3, which is localized to mitochondria is an exception. (B) Co-transfection with DNAJB chaperones could also prevent parkin C289G aggregation (*=p<0.05; **=p<0.01; ***=p<0.001; n>3 independent samples, mean ± SEM). DNAJB9 shows no prevention, due to localization of the chaperone to the ER. Expression of chaperones was detected with anti-V5 antibodies. GAPDH was used as a loading control for the soluble fraction. Co-transfection with members of the HSPA family reveals that they cannot prevent aggregation of parkin C289G. Co-transfection of none of the HSPA members caused a decrease in the HMW species of parkin C289G. Blots are analysed for parkin C289G high molecular weight species and normalised to parkin C289G (*=p<0.05; **=p<0.01; ***=p<0.001; n=3 independent samples, mean ± SEM). (B) Co-transfection with members of the HSPH family shows no prevention of aggregation of parkin C289G (*=p<0.05; **=p<0.01; ***=p<0.001; n=3 independent samples, mean ± SEM). (C) Co-transfection with BAG1 or BAG3 shows no prevention of aggregation of parkin C289G (*=p<0.05; **=p<0.01; ***=p<0.001; n=2 independent samples, mean ± SEM). -labeled cysteine and methionine for 10 minutes and chased for two hours. Parkin WT and parkin C289G were immunoprecipitated from the insoluble pellet fractions with a monoclonal flag antibody. Reduced samples were resolved by 10% SDS-PAGE. Detergent insoluble parkin WT or parkin C289G was quantified by phosphor-imaging and data was plotted as insoluble fraction (in arbitrary units (AU)). 
